Funding competition currently closed; stay tuned for new announcements.
In 2017, SCN launched a funding competition to support high-quality translational research and clinical trials in stem cell and regenerative medicine research with the anticipation of awarding approximately $4M through a peer-reviewed competition. The funding will support novel research that will ultimately realize both health and economic benefits for Canadians. See results from this competition.
In March 2018, SCN issued a Call for Letters of Intent to stem cell and regenerative medicine researchers from across Canada. This process sought promising projects that will form the basis of SCN’s research program under the Networks of Centres of Excellence and will be highlighted in the full application to be submitted later this summer. See results from this call.
SCN Research Programs
SCN supports cross-disciplinary and leading-edge research in pursuit of our vision to capitalize upon Canada’s competitive advantage in stem cells for the benefit of Canadians. SCN’s current research programs include:
Clinical Trial Research Agreement
The Clinical Trial Research Agreement supports projects that focus on novel cellular or stem cell-related therapeutic approaches to tissue repair and regeneration for specific diseases. Eligible clinical trials must be at the Phase I or II stage, and have received both Research Ethics Board and CTA approval from Health Canada. It is expected that successful projects will show incremental benefit to the patient and provide an economic analysis of the potential cost of treatment comparedto current best available standard of care.
Disease Team Research Agreement
Disease Team Research Agreements support projects that are developing novel cellular or stem cell-related therapeutic approaches to tissue repair and regeneration for specific diseases. This includes, cell-based, protein-based, small molecule based or other approaches. Proposals must clearly describe the translational bench to bedside path of the research and identify where the proposed research stands along the path.
Impact Research Agreement
The Impact Research Agreement Program has four funding streams (Translational, Clinical Translation, Commercialization and Public Policy).
Translational Impact Research Agreements support early stage translational projects that have the potential to develop novel therapeutic stem cell approaches to tissue repair and regeneration within a disease model. Projects must clearly identify the translational “bench to bedside” path of the research and where the proposed research stands along the path. Projects within this program can involve proof-of-principle experiments, development of new models, expression and epigenetic studies to understand behavior of stem and progenitor cells in disease relevant settings. Projects may also involve identification and characterization of compounds/drugs that target stem cell differentiation/proliferation with the aim to develop novel therapeutic approaches.
Clinical Translation & Accelerator Impact Research Agreements support projects that develop novel cellular or therapeutic stem cell approaches to tissue repair and regeneration within specific disease models. In addition, projects that are nearing Health Canada clinical trial initiation will also be eligible for support. Projects must clearly identify the translational “bench to bedside” path of the research and where the proposed research stands along the path. Projects that are principally focused on basic research activities are not encouraged.
Commercialization Impact Research Agreements support projects that generate novel technologies and intellectual property that have commercial value in the stem cell research or therapeutics markets.
Public Policy Impact Research Agreements support projects that address public policy issues relevant to stem cell research. Projects may also consist of a workshop or series on critical stem cell related issues, with the goal to bring together different stakeholder groups to stimulate discussion and generate briefing documents, white papers and/or policy recommendations. Examples of issues that may be addressed through the Public Policy stream include research ethics, derivation and use of human embryonic stem cells, animal models, patient rights, and use of new technologies. Applications in new or emerging areas are also welcome, for example: access and allocation issues; issues in the use of unproven cell therapies, and reimbursement issues.